CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Leica Biosystems and Advanced Cell Diagnostics announced a comprehensive partnership to develop and commercialize tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridization assays on Leica’s Bond clinical advanced staining instruments. The agreement supports Leica’s development and commercialization of fully automated RNAscope-based companion diagnostic tests in partnership with biopharmaceutical companies.
The combination of ACD’s RNAscope technology with Leica’s fully automated pathology solutions allows companies and laboratories in clinical markets to integrate the new RNA-based biomarker tests into the existing pathology workflow. These tests will be co-branded and commercialized exclusively by Leica Biosystems for use in clinical laboratories around the world.
The RNAscope LS probes and reagents, running on the research use only Bond RX instrument, will also be upgraded to ready-to-use kits with streamlined software. The RNAscope LS products will continue to be branded and commercialized exclusively by ACD.
Leica Biosystems, 800-248-0123